https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ABiosimilar%2F34%2Fen 2026-07-03T19:29:23Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Translations:Biosimilar/34/en&diff=130343&oldid=prev 2024-03-20T00:54:06Z

<p>Importing a new version from external source</p> <p><b>New page</b></p><div>{| class=&quot;wikitable&quot;<br /> |-<br /> ! Date of Biosimilar FDA Approval !! Biosimilar Product !! Original Product<br /> |-<br /> | March 2015 || filgrastim-sndz/Zarxio || [[filgrastim]]/Neupogen<br /> |-<br /> | April 2016 || infliximab-dyyb/Inflectra || [[infliximab]]/Remicade<br /> |-<br /> | August 2016 || etanercept-szzs/Erelzi || [[etanercept]]/Enbrel<br /> |-<br /> | September 2016 || adalimumab-atto/Amjevita || [[adalimumab]]/Humira<br /> |-<br /> | April 2017 || infliximab-abda/Renflexis || [[infliximab]]/Remicade<br /> |-<br /> | August 2017 || adalimumab-adbm/Cyltezo || [[adalimumab]]/Humira<br /> |-<br /> | September 2017 || bevacizumab-awwb/Mvasi || [[bevacizumab]]/Avastin<br /> |-<br /> | December 2017 || trastuzumab-dkst/Ogivri || [[trastuzumab]]/Herceptin<br /> |-<br /> | December 2017 || infliximab-qbtx/Ixifi || [[infliximab]]/Remicade<br /> |-<br /> | May 2018 || epoetin alfa-epbx/Retacrit || [[epoetin alfa]]/Procrit<br /> |-<br /> |June 2018 || pegfilgrastim-jmdb/Fulphila || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | July 2018 || filgrastim-aafi/Nivestym || [[filgrastim]]/Neupogen<br /> |-<br /> | October 2018 || adalimumab-adaz/Hyrimoz || [[adalimumab]]/Humira<br /> |-<br /> | November 2018 || pegfilgrastim-cbqv/Udenyca || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | November 2018 || rituximab-abbs/Truxima || [[rituximab]]/Rituxan<br /> |-<br /> | December 2018 || trastuzumab-pkrb/Herzuma || [[trastuzumab]]/Herceptin<br /> |-<br /> | January 2019 || trastuzumab-dttb/Ontruzant || [[trastuzumab]]/Herceptin<br /> |-<br /> | March 2019 || trastuzumab-qyyp/Trazimera || [[trastuzumab]]/Herceptin<br /> |-<br /> | April 2019 || etanercept-ykro/Eticovo || [[etanercept]]/Enbrel<br /> |-<br /> | June 2019 || trastuzumab-anns/Kanjinti || [[trastuzumab]]/Herceptin<br /> |-<br /> | June 2019 || bevacizumab-bvzr/Zirabev || [[bevacizumab]]/Avastin<br /> |-<br /> | July 2019 || rituximab-pvvr/Ruxience || [[rituximab]]/Rituxan<br /> |-<br /> | July 2019 || adalimumab-bwwd/Hadlima || [[adalimumab]]/Humira<br /> |-<br /> | November 2019 || pegfilgrastim-bmez/Ziextenzo || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | November 2019 || adalimumab-afzb/Abrilada || [[adalimumab]]/Humira<br /> |-<br /> | December 2019 || infliximab-axxq/Avsola || [[infliximab]]/Remicade<br /> |-<br /> | June 2020 || pegfilgrastim-apgf/Nyvepria || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | July 2020 || adalimumab-fkjp/Hulio || [[adalimumab]]/Humira<br /> |-<br /> | December 2020 || rituximab-arrx/Riabni || [[rituximab]]/Rituxan<br /> |-<br /> | July 2021|| insulin glargine-yfgn/Semglee || [[insulin glargine]]/Lantus<br /> |-<br /> | September 2021 || ranibizumab-nuna/Byooviz || [[ranibizumab]]/Lucentis<br /> |-<br /> | December 2021 || insulin glargine-aglr/Rezvoglar || [[insulin glargine]]/Lantus<br /> |-<br /> | December 2021 || adalimumab-aqvh/Yusimry || [[adalimumab]]/Humira<br /> |-<br /> | February 2022 || filgrastim-ayow/Releuko || [[filgrastim]]/Neupogen<br /> |-<br /> | April 2022 || bevacizumab-maly/Alymsys || [[bevacizumab]]/Avastin<br /> |-<br /> | May 2022 || pegfilgrastim-pbbk/Fylnetra || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | August 2022 || ranibizumab-eqrn/Cimerli || [[ranibizumab]]/Lucentis<br /> |-<br /> | September 2022|| pegfilgrastim-fpgk/Stimufend || [[pegfilgrastim]]/Neulasta<br /> |-<br /> | September 2022 || bevacizumab-adcd/Vegzelma || [[bevacizumab]]/Avastin<br /> |-<br /> | December 2022 || adalimumab-aacf/Idacio || [[adalimumab]]/Humira<br /> |-<br /> | May 2023 || adalimumab-aaty/Yuflyma || [[adalimumab]]/Humira<br /> |-<br /> | August 2023 || natalizumab-sztn/Tyruko || [[natalizumab]]/Tysabri<br /> |-<br /> | September 2023 || tocilizumab-bavi/Tofidence || [[tocilizumab]]/Actemra<br /> |-<br /> | October 2023 || ustekinumab-auub/Wezlana || [[ustekinumab]]/Stelara<br /> |-<br /> | December 2023 || bevacizumab-tnjn/Avzivi || [[bevacizumab]]/Avastin<br /> |-<br /> | February 2024 || adalimumab-ryvk/Simlandi || [[adalimumab]]/Humira<br /> |-<br /> | March 2024 || denosumab-bbdz/Jubbonti || [[denosumab]]/Prolia<br /> |-<br /> | March 2024 || denosumab-bbdz/Wyost || [[denosumab]]/Xgeva<br /> |}</div>

FuzzyBot